Analyst Ratings for Ironwood Pharmaceuticals (IRWD) [Neutrals]
IRWD Rating Summary
IRWD Price Target Summary
- Highest: $24.00 (Credit Suisse)
- Lowest: $8.00 (Cantor Fitzgerald)
- Average: $15.30
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
$15.30 (+6.3%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/6/2013 | Cowen | Downgrade | Neutral (Outperform) |
N/A (N/A) |
14.61 | 14.39 | -1.51% | Details |
| 4/24/2013 | Morgan Stanley | Downgrade | Equalweight (Overweight) |
N/A (N/A) |
16.77 | 14.39 | -14.19% | Details |
| 1/31/2013 | Janney Montgomery Scott | New Coverage | Neutral (N/A) |
14.00 (N/A) |
12.91 | 14.39 | 11.46% | Details |
| 12/18/2012 | WallachBeth Capital | New Coverage | Hold (N/A) |
10.00 (N/A) |
10.96 | 14.39 | 31.3% | Details |
| 5/15/2012 | Jefferies | New Coverage | Hold (N/A) |
13.00 (N/A) |
13.20 | 14.39 | 9.02% | Details |
| 1/6/2012 | ThinkEquity | New Coverage | Hold (N/A) |
13.00 (N/A) |
11.98 | 14.39 | 20.12% | Details |
| 5/26/2011 | Duncan Williams | New Coverage | Hold (N/A) |
N/A (N/A) |
15.01 | 14.39 | -4.13% | Details |
| 9/14/2010 | BofA/Merrill Lynch | Downgrade | Neutral (N/A) |
N/A (N/A) |
9.75 | 14.39 | 47.59% | Details |
